Drug News

Added 13 hours ago Drug news

AZD 6244 filed with FDA for NF1 and plexiform neurofibromas and given priority review.- AstraZeneca and Merck Inc

AstraZeneca and Merck Inc announced that the FDA has accepted a New Drug Application (NDA) and granted Priority Review for...

Added 13 hours ago Drug news

Phase III CLEAR Wisdom trial of EYC 1002(bempedoic acid 180 mg) in atherosclerotic CV disease + HFH published in JAMA.- Daiichi Sankyo

Daiichi Sankyo Europe has announced the publication of results from the Phase III CLEAR Wisdom trial of EYC 1002 (bempedoic...

Added 13 hours ago Drug news

Phase III study of Nucala meets primary endpoint in Hypereosinophilic Syndrome.- GSK

GlaxoSmithKline announced positive results from the pivotal study of Nucala (mepolizumab) in the treatment of patients living with Hypereosinophilic Syndrome...

Added 13 hours ago Drug news

Study 017 trial of safety and efficacy of YKP 3089 in focal seizures published in The Lancet Neurology.- SK Life Science

SK Life Science announced The Lancet Neurology has published results from Study 017, a multicenter, double-blind, randomized, placebo-controlled, dose-response study...

Added 1 day ago Drug news

Boehringer and Eli Lilly announce outcome of FDA advisory committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes.

The FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg...

Added 2 days ago Drug news

Lilly presents 52-week head-to-head (SPIRIT-H2H) data from Taltz v. Humira trial in psoriatic arthritis.

Eli Lilly and Company announced the 52-week results from the Phase IIIb/IV SPIRIT-Head-to-Head (H2H) study of Taltz (ixekizumab) versus Humira...

Added 2 days ago Drug news

Actelion Pharma withdraws filing of Opsumit for CTEPH

Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw...

Added 2 days ago Drug news

COAST-X phase III trial of Taltz meets primary and secondary endpoints in axial spondyloarthritis.- Eli Lilly

Eli Lilly presented detailed results demonstrating Taltz (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week...

Added 2 days ago Drug news

GW Pharmaceuticals receives positive NICE recommendation for Epidyolex for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

GW Pharmaceuticals plc announces that two of its medicines, Epidyolex (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by...

Added 2 days ago Drug news

Phase III CONFIRM study of Variquel meets primary endpoint in hepatorenal syndrome type 1.- Mallinckrodt

Mallinckrodt announced results from its pivotal Phase III CONFIRM study to assess the efficacy and safety of its investigational agent...

Search all news articles